Previous Close | 5.43 |
Open | 5.45 |
Bid | 5.33 x 1300 |
Ask | 5.65 x 900 |
Day's Range | 5.41 - 5.63 |
52 Week Range | 4.22 - 8.79 |
Volume | |
Avg. Volume | 443,574 |
Market Cap | 398.824M |
Beta (5Y Monthly) | 0.59 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.08 |
Earnings Date | Feb 29, 2024 - Mar 04, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | May 15, 2023 |
1y Target Est | N/A |
Subscribe to Yahoo Finance Plus to view Fair Value for SIGA
Passive investing in an index fund is a good way to ensure your own returns roughly match the overall market. When you...
- In Third Quarter, SIGA Received U.S. Government Orders for Approximately $113 Million of Oral TPOXX and $25 Million of IV TPOXX® - - In October, Joint Procurement Framework Contract was signed by European Commission with Anticipated Initial Orders by Participating Countries of Approximately $18 Million for Oral TPOXX® (Tecovirimat) - - Corporate Update Conference Call Today at 4:30 PM ET - NEW YORK, Nov. 07, 2023 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-s
NEW YORK, Oct. 26, 2023 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Tuesday, November 7th, 2023. Participating on the call will be Phil Gomez, Chief Executive Officer, Dennis Hruby, Chief Scientific Officer, Dr. Jay Varma, Chief Medical Officer and Daniel Luckshire, Chief Financial Officer. A live webcast of the